6th$Annual$Maritime$Natural$Products$Conference$ $ Monday$$August$18th,$2014$ ! 6:00!–!8:00!pm!!

First Page		Document Content
Date: 2014-08-13 15:02:31 Sumac Anthocyanin Natural product Eribulin Structural elucidation Biosynthesis Amino acid Nuclear magnetic resonance Chemistry Science Spices		6th$Annual$Maritime$Natural$Products$Conference$ $ Monday$$August$18th,$2014$ ! 6:00!–!8:00!pm!! Add to Reading List Source URL: maritimenaturalproducts.files.wordpress.com Download Document from Source Website File Size: 1,17 MB Share Document on Facebook

	Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th DocID: 1uZFZ - View Document
	EISAI UND PIQUR UNTERZEICHNEN EINEN BAHNBRECHENDEN KOOPERATIONSVERTRAG ÜBER DIE UNTERSUCHUNG VON HALAVEN® (ERIBULIN) UND PQR309 BEI SCHWER BEHANDELBAREM BRUSTKREBS Der Vertrag sieht die Anwendung von Eribulin in Kombin DocID: 1rWLP - View Document
	EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i DocID: 1rhhk - View Document
	Legend Open to Accrual Pending Accrual on Hold Advanced Breast Cancer DocID: 18i4E - View Document
	January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in DocID: 13EAt - View Document